Bordeaux Integrated Oncology Research (BRIO) Part of the French National Cancer Institute (INCa) Integrated Research Sites Network (SIRICs)
|
|
- Cori Harrington
- 6 years ago
- Views:
Transcription
1 Bordeaux Integrated Oncology Research (BRIO) Part of the French National Cancer Institute (INCa) Integrated Research Sites Network (SIRICs) 1
2 Labellised between 2011 & Integrated Cancer Research Sites (SIRICs) were created by the French National Cancer Institute (INCa) between 2011 & 2012 SIRICs implementation aims to offer new operational conditions to cancer research, in order to optimise and accelerate the production of new knowledge and favor its dissemination and applications in cancer care management. INCa (Institut National du Cancer) 2 2
3 To formulate and implement integrated research programmes by: Modifiez les styles du texte du masque Sharing questions and objectives Creating synergies Improving patient management France s Integrated Cancer Research Sites missions Deuxième niveau Troisième niveau To disseminate and transfer research results by: Communicating and transfering results Creating interfaces between health care Quatrième professionals niveau Cinquième niveau Facilitating bench-to-the bedside transition Optimising access to infrastructures and shared services 17/04/
4 Our partners Hospitals Research institutions University Regional institutions 4
5 Integrated Cancer Research in Bordeaux 5
6 BRIO at a glance projects 16 research teams 33 research staff directly funded by BRIO 150 research staff working on BRIO projects 7.5 million euros over 5 years 6
7 Bio-Informatics In-Vivo Research Epidemiology and public health Databases Personalised Medicine Human and Social Sciences Basic Research Implementation Strategy Breast Sarcoma PROGRAMMES 6 Research programmes Myeloid Leukemia Liver 7 Strategic axes Innovative Molecular Targets Geriatric Oncology STRATEGIC AXES 7
8 Bio-Informatics In-Vivo Research Epidemiology and public health Databases Personalised Medicine Human and Social Sciences Basic Research 6 integrated Research Programmes Breast cancer Sarcoma Myeloid Leukemia PROGRAMMES Breast Sarcoma Myeloid Leukemia Liver cancer Liver Innovative molecular targets Innovative Molecular Targets Geriatric Oncology Geriatric oncology 8 STRATEGIC AXES 8
9 Breast Cancer (Dr. H Bonnefoi) Implementation of new neo-adjuvant treatments in the Aquitaine and Limousin regions Translational research based on predictive markers, identification of new potential targets and use of new therapies Psychological distress evaluation of patients treated by neo-adjuvant therapies and identification of new interventional techniques 9
10 Innovative Molecular Targets Promote early clinical trials (Dr. A Italiano) Accelerate translational research through the identification of predictive biomarkers and resistance mechanisms to molecules under development Develop translational imaging, and more specifically the early prediction of treatments responses 10 10
11 Myeloid Leukemia (Dr. FX Mahon) Understand the mechanisms of formation of Chronic Myeloid Leukaemia (CML) to identify new therapeutic targets Understand the mechanisms of resistance linked to use of kinase inhibitors and identify alternative treatments Translational and clinical research on chronic and acute myeloid leukaemias to select appropriate treatments 11 11
12 Sarcoma (Dr. JM Coindre) Evaluate medical practices (diagnostic and treatment) and propose improvements via the French Sarcoma network Improve the efficacy and quality of locoregional treatments Improve the understanding of sarcoma biology in order to implement better predictive and diagnostic tools Promote clinical innovation and the development of adequate criterias to evaluate these new therapeutic tools 12 12
13 Geriatric Oncology (Dr. P Soubeyran) Optimise treatment selection through the use of optimal data including a geriatric evaluation Introduce adapted treatment rules, based on geriatric experience and allowing a more precise medical intervention Identify potential treatment solutions based on biological understanding of the disease through elderly-specific tumors (stem cells and immunology) Identification of and intervention on societal and psychological hurdles preventing an optimal treatment of elderly patients 13 13
14 Liver Cancer (Dr. J Rosenbaum) Characterise the mechanisms of liver cancer formation and identification of new therapeutic targets Improve Sorafenib efficacy via the characterisation of response markers Conduct clinical trials and explore innovative therapies Characterise non fibrotic hepatocellular carcinoma through epidemiological and biological studies Analyse medical practices and improve the understanding of risk factors Improve locoregional treatments for the treatment of liver cancer 14 14
15 Bio-Informatics In-Vivo Research Epidemiology and public health Databases Personalised Medicine Human and Social Sciences Basic Research 7 strategic axes PROGRAMMES Bioinformatics In-vivo research Outcome research Human and social sciences Breast Sarcoma Myeloid Leukemia Liver Databases Innovative Molecular Targets Personalised medicine Geriatric Oncology Basic research 15 STRATEGIC AXES 15 15
16 Knowledge dissemination and transfert Objectives : Research results dissemination to the relevant target populations Promote the interactions between groups Transfer results to the industry whenever applicable Research result dissemination Collaborations academics, industrial Researchers, students Health care professionals Patients General population Improve industrial collaborations Support start-ups Develop translational research Search fundings Improvement of patient care Better understanding of the disease, the treatments and the research 16 16
17 Collaborate with BRIO SIRIC What BRIO offers you: A network of multidisciplinary high-level researchers Access to clinicians and patients A SIRIC label, its visibility and a support for your grant requests Assistance to consolidation or transfer your research with academic or industrial partnerships Support to start-ups What BRIO is looking for: Partnerships related to cancer and specifically to the 6 programmes, seven axes and the knowledge dissemination programme Academic research in cancer biology, clinical, epidemiological, public health, human and social sciences Industrial research: biotech, pharma, diagnostics, biomarkers, medical devices, ICTs Collaborations with researchers, healthcare workers or patients associations Contact Dr Paolo Meoni - General Manager BRIO p.meoni@bordeaux.unicancer.fr Phone: (+33)
SIRIC BRIO. Integrated Cancer Research Site
SIRIC BRIO Integrated Cancer Research Site 1 SIRICs were labellised between 2011 & 2012 SIRICs implementation aims to offer new operational conditions to cancer research, in order to optimise and accelerate
More informationOPTIMISING COLLABORATIONS TO FOSTER INNOVATION. R&D UNICANCER, the leading French academic clinical research organisation in oncology
OPTIMISING COLLABORATIONS TO FOSTER INNOVATION R&D UNICANCER, the leading French academic clinical research organisation in oncology ACADEMIC EXCELLENCE IN CANCER RESEARCH, FOR THE BENEFIT OF THE PATIENTS
More informationC A N C É R O P Ô L E L Y O N A U V E R G N E R H Ô N E - A L P E S
Cancer Research Cluster to Facilitate and Structure Oncology Research C A N C É R O P Ô L E L Y O N A U V E R G N E R H Ô N E - A L P E S s P E E D I N G U P P R O G R E S S CANCÉROPÔLE LYON AUVERGNE RHÔNE-ALPES
More informationHorizon Introduction. Alex Harris Medical Research Council
Horizon 2020 - Introduction Alex Harris Medical Research Council Agenda MRC and Horizon 2020 UK Success Rate (FP7 Health) What is Horizon 2020? The Horizon 2020 Health Challenge NCP support MRC and Horizon
More informationWhat EU research policy can do for conditions such as chronic pain?
The EU Framework Programme for Research and Innovation HORIZON 2020 What EU research policy can do for conditions such as chronic pain? K Berkouk, PhD Deputy Head of Unit, Non-communicable diseases and
More informationCancer Research in the EU Framework Programmes for RTD
Cancer Research in the EU Framework Programmes for RTD Action against cancer: European platform Maria Vidal, MD, PhD Deputy Head of Unit Medical and public health research Health Directorate DG Research
More informationCELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH
CELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH Our MISSION Building on our tradition Reaching out to the community Doing our best to serve, care and heal Together, we aim
More informationR&D UNICANCER Oncology Research
R&D UNICANCER Oncology Research R&D UNICANCER A national academic sponsor dedicated to clinical research in oncology Our missions: Promote and accelerate Clinical Research in Oncology, especially in areas
More informationAutism: The Federal Effort. Thomas R. Insel, M.D. National Institute of Mental Health NIH/DHHS 12/16/05
Autism: The Federal Effort Thomas R. Insel, M.D. National Institute of Mental Health NIH/DHHS 12/16/05 The Inter-Agency Autism Coordinating Committee NIH (NIMH, NICHD, NINDS, NIEHS, NIDCD) CDC (Agency
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationCYPRUS PRESIDENCY OF THE COUNCIL OF THE EU
CYPRUS PRESIDENCY OF THE COUNCIL OF THE EU July December 2012 Research Symposium on Digestive and Liver Diseases Brussels, 18 September 2012 Dr Myrto Azina- Chronides Ministry of Health Cyprus Digestive
More informationThe European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing
The European Framework Program for Research & Innovation: Horizon 2020: Health, demographic change & wellbeing Sasha Hugentobler National Contact Point Health Euresearch Head Office phone +41 31 380 60
More informationUC HEALTH RESEARCH INSTITUTE STRATEGIC PLAN
UC HEALTH RESEARCH INSTITUTE STRATEGIC PLAN 2016-2020 1 2 OUR VISION Excellence in research is at the core of our vision for UC-Health Research Institute (HRI) which brings together critical mass in biomedicine,
More informationTowards tailored and targeted asthma self-management using mobile technologies
Towards tailored and targeted asthma self-management using mobile technologies Funded by the European Union Asthma: the problem Asthma is a lifelong chronic disease caused by inflammation of the airways,
More informationThe summit and its purpose
Sponsors: 1 The summit and its purpose The Translational Hearing Research Summit: Biological and Pharmacological Approaches was an international summit that gathered 159 delegates, from 14 countries to
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationPersonalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
More informationDelphi Survey Results. MPIs: Drs. William Dale, Arti Hurria, Supriya Mohile
Delphi Survey Results MPIs: Drs. William Dale, Arti Hurria, Supriya Mohile Cancer and Aging Research Group (CARG) A Delphi Investigation Of Geriatric Oncology Experts Sustainable Infrastructure That Supports
More informationImplications for public health research. Professor Bernie Hannigan Director - Research, Translation & Innovation
Implications for public health research Professor Bernie Hannigan Director - Research, Translation & Innovation Our mission To protect and improve the nation s health and to address inequalities...working
More informationDevelopment of Geriatric Oncology in France
Development of Geriatric Oncology in France Pr Pierre Soubeyran Institut Bergonié, Bordeaux, France Epidemiology French population, 2013 9% older than 75 (10.9% females, 7% males) Number of cancer cases
More informationAn evidence-based analysis to characterise the benefits of personalised medicines to patients, society and healthcare systems.
An evidence-based analysis to characterise the benefits of personalised medicines to patients, society and healthcare systems July 2018 s Purpose of this report The European Biopharmaceutical Enterprises
More informationHCV Elimination in Egypt
HCV Elimination in Egypt Prof. Gamal Esmat Prof. Hepatology &Ex. Vice President of Cairo University, Egypt Member of WHO Strategic Committee for Viral Hepatitis www.gamalesmat.com Disclosure Slide Advisory
More informationPfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Please note that all information in this document is also disclosed in the overall report on Pfizer
More information7th November, Labex TRAIL
7th November, 2014 Labex TRAIL The Translational Research and Advanced Imaging Laboratory (TRAIL) program seeks to facilitate interdisciplinary, collaborative basic and clinical research in image-based
More informationTHE GUSTAVE ROUSSY / INSERM PLATFORM
Retrospective dose reconstruction in external beam radiotherapy for use in epidemiology: THE GUSTAVE ROUSSY / INSERM PLATFORM Dimitri Lefkopoulos PhD, Medical Physics Medical physics Department Gustave
More informationFORSKNINGSINFRASTRUKTUR - 12 FEBRUAR. Ketil F. Widerberg
FORSKNINGSINFRASTRUKTUR - 12 FEBRUAR Ketil F. Widerberg AGENDA Oslo Cancer Cluster Area of successful infrastructure Example immuno-oncology Area of potential Example precision medicine SIDE 2 DATO XX.XX.XXXX
More informationResearch For the Future. Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer
Research For the Future Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer 1 2 ATTACKING CANCER FROM EVERY ANGLE 3 CANCER PREVENTION STUDIES (CPS) Intramural Research Smoking Obesity
More informationTECHNOLOGICAL OPPORTUNITIES AND
TECHNOLOGICAL OPPORTUNITIES AND INNOVATIONS TO IMPROVE EPILEPSY DIAGNOSIS AND MANAGEMENT THE ROLE OF SMES European Forum on Epilepsy Research Dublin 2013 Emmanuel Martin Director Genomics Services 1 Operations
More informationThe DATECAN initiative
The DATECAN initiative Definition and Assessment of Time-to-event Endpoints in CANcer trials Carine BELLERA INSERM U1219 et Institut Bergonié, Bordeaux On behalf of the DATECAN steering committee Genesis
More informationBRIO partner institutions
BRIO partner institutions o Institut Bergonié The Institut Bergonié, now called Bergonié, was officially opened on April 17th 1923 as the Fondation Bergonié, the centre for cancer care in Bordeaux, and
More informationIMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM
IMI2 T1DM Call Topic Text: Translational approaches to disease modifying therapy of T1DM Dr Anke M Schulte, Head of Islet Biology Department Sanofi-Diabetes Frankfurt, Germany 11th of July, 2014 General
More informationOPTIMISING COLLABORATIONS TO FOSTER INNOVATION. R&D UNICANCER, the leading French academic clinical research organisation in oncology
OPTIMISING COLLABORATIONS TO FOSTER INNOVATION R&D UNICANCER, the leading French academic clinical research organisation in oncology ACADEMIC EXCELLENCE IN CANCER RESEARCH, FOR THE BENEFIT OF THE PATIENTS
More informationConsolidated plan for the Centre for Global Health
Consolidated plan for the Centre for Global Health Presentation to the Faculty of Medicine Board 8 May, 2018 AS Winkler Centre for Global Health 1 Mission The mission of the CGH is to facilitate high quality
More informationPRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER
PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER This collaboration creates the world s first clinically reliable and
More informationIntegrating Medical and Social Support for Elderly System & Technology Enabled Service Innovations. Dr Christina MAW Hospital Authority, Hong Kong
Integrating Medical and Social Support for Elderly System & Technology Enabled Service Innovations Dr Christina MAW Hospital Authority, Hong Kong Hospital Authority (HA) of Hong Kong A statutory body responsible
More informationClinical research in. Respiratory medicine. How to be involved
Clinical research in Respiratory medicine How to be involved Research in respiratory medicine in Northern Ireland The Northern Ireland Clinical Research Network (NICRN) undertakes research in respiratory
More informationMental Health. Patrizia Tosetti, PhD Unit F2 Medical Research DG Research and Innovation
European efforts in Mental Health research Patrizia Tosetti, PhD Unit F2 Medical Research DG Research and Innovation European Commission Conference on Psychotherapy in Europe EP, Brussels 9 February 2012
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationFuture of diabetes research in the EU- the EC perspectives
Future of diabetes research in the EU- the EC perspectives Dr Karim Berkouk, Deputy Head of Unit DG for Health Directorate European Commission Overview Challenges in diabetes Research in diabetes at EU
More informationThe Innovative Medicines Initiative: an engine for therapeutic innovation
The Innovative Medicines Initiative: an engine for therapeutic innovation Michel Goldman 26.11.2014 Brussels Bringing health-related life science and technology sectors into IMI2 The pillars of innovation
More informationSmartLife - Addressing the Needs of People with Diabetes (PwD) Using Machine Learning
SmartLife - Addressing the Needs of People with Diabetes (PwD) Using Machine Learning Tina Woerner, Roche Alexander Buesser, IBM September, 19th 2018 1 Roche is a Basel based, global pharmaceutical company
More informationNew Horizons for Vaccine R&D&I in Europe
New Horizons for Vaccine R&D&I in Europe Health, Demographic Change and Wellbeing Ruxandra Draghia-Akli MD, PhD Directorate E - Health Research DG - Research & Innovation European Commission Why EU support
More informationChildren s Cancer Institute Strategic Plan It s not if. It s when. STRATEGIC PLAN
Children s Cancer Institute Strategic Plan 2018-2022 It s not if. It s when. STRATEGIC PLAN 2018 2022 We can and will cure childhood cancer in the foreseeable future. PROFESSOR MICHELLE HABER AM EXECUTIVE
More informationElekta - a partner and world-leading supplier
Experience Elekta Elekta - a partner and world-leading supplier of clinical solutions for image guided radiation therapy, stereotactic radiotherapy, radiosurgery and brachytherapy, as well as advanced
More informationPCI Biotech press release 24 th August Attachment
PCI Biotech press release 24 th August 2018 Attachment 1 BILE DUCT CANCER CLINICAL PHASE I STUDY Cohort IV is selected dose for pivotal study limited but promising data (per Aug 2018) Parameters 1) Average
More informationResearch and Reach-Out
MUHC Consortium for Rare Disease Research (CRDR) Rare Disease Research Day: Research and Reach-Out Thursday, February 28, 2019 Drs. Sylvia & Richard Cruess Amphitheatre & Elspeth McConnell Atrium 1001
More informationHow to faster integrate new technologies into clinical practice
How to faster integrate new technologies into clinical practice 31JAN2017 Jens Bjørheim, CMO Ultimovacs Nordic Trial Alliance Stakeholders meeting 2 Oncology New drugs Landscape The current buzz Basket
More informationNIHR Supporting collaboration in life sciences research
NIHR Supporting collaboration in life sciences research Dr Matt Hallsworth - Head of External Relations, NIHR Office for Clinical Research Infrastructure (NOCRI) Research funders build capabilities and
More informationMelanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
More informationGenomics and personalised prevention
30 September 2016 1 Genomics and personalised prevention Dr Tom Fowler, Deputy Chief Scientist & Director of Public Health European Health Forum, Gastein 29 September 2016 About me Tom Deputy Chief Scientist
More informationsunfrail the project in a nutshell
sunfrail the project in a nutshell 1 THE CHALLENGE Population ageing is accelerating rapidly worldwide, from 461 million people older than 65 years in 2004 to an estimated 2 billion people by 2050, which
More informationONTARIO CANCER PLAN
ONTARIO CANCER PLAN 2011-2015 I want to live... I m still young, many people in my family have lived to be 100. I want to be around to watch my grandchildren grow up. Screening saved my life, I tell everybody
More informationA future where everybody who develops breast cancer lives and lives well. Our vision, mission, values and five-year strategy ( )
A future where everybody who develops breast cancer lives and lives well Our vision, mission, values and five-year strategy (2017 2022) Welcome We are delighted to present Breast Cancer Now s new long-term
More informationNew Opportunities in Cancer Research National Academy of Sciences Advancing Health Research in Poland and the United States December 3, 2009
New Opportunities in Cancer Research National Academy of Sciences Advancing Health Research in Poland and the United States December 3, 2009 Anna D. Barker, Ph.D. Deputy Director, NCI Cancer is a Current
More informationDr.sc. Branka Bernard National Contact Point Member of the Programme Committee
Horizon 2020 - societal challenge 1 Health, demographic change and wellbeing Work Programme 2014-2015 Dr.sc. Branka Bernard National Contact Point Member of the Programme Committee HORIZON 2020 Work Programmes
More informationCall for Applications
2013 Knowledge Synthesis Grant Program Call for Applications Program Guidelines Overview Technology Evaluation in the Elderly Network (TVN or the Network) is a new network funded by the Government of Canada
More informationDedicated to research, education and service to patients for prevention and effective treatment of kidney disease
STRATEGIC PLAN Our Mission: Dedicated to research, education and service to patients for prevention and effective treatment of kidney disease Introduction Over the last 2 years, the Trustees undertook
More informationFuture of Diabetes Research in Europe JDRF Perspective
Future of Diabetes Research in Europe JDRF Perspective IMI-JDRF Diabetes Patient Meeting 20 May 2014 Brussels, Belgium Olivier ARNAUD, Pharm D JDRF European Research Director oarnaud@jdrf.org Future of
More informationRESEARCH EDUCATION COMMUNITY STRATEGIC PLAN
RESEARCH EDUCATION COMMUNITY STRATEGIC PLAN 2016-2021 VISION Leading the improvement of musculoskeletal health for patients across their lifespan through research and education. MISSION To enhance the
More informationPROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary
CBD Distr. GENERAL UNEP/CBD/COP/11/31 30 July 2012 ORIGINAL: ENGLISH CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY Eleventh meeting Hyderabad, India, 8 19 October 2012 Item 3.2 of
More informationClinical research in. Stroke. How to be involved
Clinical research in Stroke How to be involved Stroke research in Northern Ireland The Northern Ireland Clinical Research Network (NICRN) undertakes stroke research throughout Northern Ireland. The NICRN
More informationREPORT. A Model Clinical Trials System for the 21st Century
www.georgiacore.org www.georgiacancertrials.org REPORT A Model Clinical Trials System for the 21st Century A Response to the Institute of Medicine s 2010 Report A National Cancer Clinical Trials System
More informationTranslational Research in Oncology in the Era of Personalized Medicine and Open Science: Are the Current Funding Mechanisms Fit for Purpose?
Policy Brief Draft- Funding mechanisms: a case study on Translational Oncology Julio E. Celis Member of RISE Dainius Pavalkis Member of RISE This document has been prepared for the European Commission
More information2014 Towards an HIV Cure symposium Melbourne The Role of a Public-Private Partnership in HIV Cure
2014 Towards an HIV Cure symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San Francisco Cure Interventions that Can Be Used Around
More informationI, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association
I, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association (MLA), submit this statement on behalf of MLA and the Association of Academic Health Sciences Libraries (AAHSL).
More informationSuccessful collaboration for research development between the NIH and patient organisations
Successful collaboration for research development between the NIH and patient organisations Stephen C. Groft, Pharm.D. Office of Rare Diseases s of Health Department of Health and Human Services EURORDIS
More informationOUR STRATEGIC PLAN
OUR STRATEGIC PLAN 2017-2021 Changing lives through innovation and excellence IHMRI ABOUT US We re front line innovators: As the only independent medical research institute (MRI) in the Illawarra region
More informationTREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal.
TREAT U is a spin-off from the University of Coimbra, founded in January 2010, and headquartered in Coimbra, Portugal. MISSION & VISION Our mission is to develop more effective strategies and safer products
More informationat the University Hospital (CHU) of Besançon
CHRU centre hospitalier régional universitaire Research & Innovation at the University Hospital (CHU) of Besançon THINK, INNOVATE, DIFFUSE, SHARE Meeting health challenges for better care Biotherapy module
More informationFunding research for the future
Funding research for the future Dr Helen Compton (helen.compton@nihr.ac.uk) Stakeholder Engagement Manager NIHR, Central Commissioning Facility The future of health and social care depends on today's research
More informationArmstrong, Bruce (Prof.)
Presenter: Armstrong, Bruce (Prof.) Title of Lecture: Cancer Control Research COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material has been reproduced and communicated to you by or
More informationNexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase II Study in Advanced Breast Cancer: Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement
More informationThe Contribution of Health Industry to the Expansion of the Country s Development Perspective
17 th Annual Conference HealthWorld 2018 The Contribution of Health Industry to the Expansion of the Country s Development Perspective 11.06.18 Makis Papataxiarchis President, Pharma Innovation Forum,
More informationFrom IMI to IMI2. Hugh Laverty Senior Scientific Project Manager
From IMI to IMI2 Hugh Laverty Senior Scientific Project Manager FitForHealth June 2014 Innovative Medicines Initiative: Joining forces in the healthcare sector The biggest public/private partnership in
More informationNetworking Clinical Trials Anna Shevlin, Clinical Trial Liaison Officer
Networking Clinical Trials Anna Shevlin, Clinical Trial Liaison Officer HRB CRCI International Clinical Trial Networks Networking Clinical Trials Clinical Research Infrastructure Disease Clinical Research
More informationR e s e a r c h S t r a t e g y
Sheffield Teaching Hospitals NHS Foundation Trust Academic Directorate of Specialised Cancer R e s e a r c h S t r a t e g y Academic Directorate of Specialised Cancer Research Strategy Executive Summary
More informationA multi-stakeholder partnership initiative. 10 February 2012
A multi-stakeholder partnership initiative 10 February 2012 1 History 39 recommendations on stakeholder actions and public policies:» 8 addressing regulatory barriers in rare cancer care» 11 addressing
More informationRoche at a Glance An Introduction to our Company. February 2013
Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active
More informationEIP-AHA A3 Action Group F2F Meeting SUNFRAIL Preliminary Results
EIP-AHA A3 Action Group F2F Meeting SUNFRAIL Preliminary Results University of Valencia Emilia-Romagna Region Mirca Barbolini Marcello Maggio & SUNFRAIL TEAM Valencia, 29 th. June 2017 SUNFRAIL Project
More informationThe 100,000 Genomes Project
The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England
More informationAccelerating Translation at Dana-Farber Cancer Institute*
Accelerating Translation at Dana-Farber Cancer Institute* *and our partner institutions February 12, 2013 Edward J Benz JR, MD Dana Farber Cancer Institute 1 2 Academic Structure All Dana-Farber faculty
More informationThe National Academies
The National Academies Building the 21 st Century: U.S. China Cooperation on Science Technology and Innovation Anna D. Barker, PhD Deputy Director, NCI May 18, 2010 By 2020, Cancer Could Kill 10.3 Million
More informationPersonalised Healthcare. will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D
Personalised Healthcare x will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D Personalised Healthcare It is delivering! Bob Holland Head of Personalised
More informationUsing the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment
Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Rachael Eckles, JD/MA Director, Regulatory Policy Bristol-Myers Squibb August 10,
More information"Giancarlo Rastelli Lecture"
"Giancarlo Rastelli Lecture" Surgical treatment of Malpositions of the Great Arteries Pascal Vouhé Giancarlo Rastelli (1933 1970) Cliquez pour modifier les styles du texte du masque Deuxième niveau Troisième
More informationJOIN US TO INTEGRATE CLINICAL RESEARCH AND HEALTH CARE
JOIN US TO INTEGRATE CLINICAL RESEARCH AND HEALTH CARE #BridgeTheGap April 4-5, 2018 National Harbor, MD bridgingclinical.com LET'S BUILD A BRIDGE Work with us to bridge the gap between clinical research
More informationA2 Action Group on Personalized Health Management and Falls Prevention
1 Authors Nick Guldemond, AG A2 Coordination Team Chair Maite Ferrando, AG A2 Promoter 2015-2016 (CSA PROEIPAHA) Valentina Tageo, AG A2 Secretariat Support Service 2015-2016 (CSA PROEIPAHA) With many thanks
More informationDissemination and Implementation Research in Diabetes and Obesity. Christine Hunter National Institute of Diabetes and Digestive and Kidney Diseases
Dissemination and Implementation Research in Diabetes and Obesity Christine Hunter National Institute of Diabetes and Digestive and Kidney Diseases Take Home Points Partnerships and existing infrastructure
More informationAustralasian Sleep Association
Australasian Sleep Association Submission to The Government s Review Panel Mr Simon McKeon, Prof. Henry Brodaty AO, Prof. Ian Frazer, Prof. Melissa Little, Ms Elizabeth Alexander AM and Mr Bill Ferris
More informationPrevention policy of French National Pension Insurance Fund - Cnav. Eu Falls Festival 2016 Bologna, Italy
Prevention policy of French National Pension Insurance Fund - Cnav Eu Falls Festival 2016 Bologna, Italy Prevention policy of French National Pension Insurance Fund - Cnav Eu Falls Festival 2016 Bologna,
More informationHealthy Ageing &Mental Health
RAJAGIRI COLLEGE OF SOCIAL SCIENCES (AUTONOMOUS) Jointly Organised by RAJAGIRI COLLEGE OF SOCIAL SCIENCES (AUTONOMOUS) International Conference on Healthy Ageing &Mental Health 4, 5 & 6 January 2017 International
More informationRare cancers Medical oncologist Point of View
Rare cancers Medical oncologist Point of View Isabelle Ray-Coquard, MD PhD Centre Léon Bérard GINECO & Université Claude Bernard Lyon I Identified factors to explain medical practices Initial Medical school
More informationImplementing international training programs for oncology research development
Implementing international training programs for oncology research development Kenneth S. Cohen, M.D. Assistant Professor of Medicine Program Director, Adult Hematology/Oncology Fellowship Program Section
More informationService Improvement - Strategic. Service Improvement - Strategic. Regional Oncology Communications and Health Promotions
Service Improvement - Strategic Service Improvement - Strategic Regional Oncology Communications and Health Promotions Development of Radiation Oncology Services The evaluation process for the development
More informationTranslating Duke Health. Accelerating discovery and its translation
Translating Duke Health Accelerating discovery and its translation Translating Duke Health Biomedical discovery is accelerating innovative and revolutionary advancements in our understanding of human biology,
More informationONCOLOGY NURSING SOCIETY RESEARCH AGENDA. M. Tish Knobf, PhD, RN, AOCN, FAAN ONS Research Agenda Team Leader
ONCOLOGY NURSING SOCIETY 2014 2018 RESEARCH AGENDA M. Tish Knobf, PhD, RN, AOCN, FAAN ONS Research Agenda Team Leader Content Leaders Mary E. Cooley, PhD, RN, FAAN Sonia Duffy, PhD, RN, FAAN Ardith Doorenbos,
More informationNASH Regulatory Landscape. Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH
NASH Regulatory Landscape Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH Disclosures Liver Forum sponsors (last slides) Advisory (Sanofi) Miller_July 7_2017 www.forumresearch.org
More informationTHE CANADA-ISRAEL TRANS-ATLANTIC COLLABORATION FOR BRAIN STUDIES
DISCUSSION PAPER THE CANADA-ISRAEL TRANS-ATLANTIC COLLABORATION FOR BRAIN STUDIES A Collaborative Research Partnership between Dalhousie University and Ben-Gurion University of the Negev WHERE BREAKTHROUGHS
More informationSTRATEGIC PLAN
STRATEGIC PLAN 2016 2020 Promoting and supporting excellence in research www.immunology.org BSI STRATEGY 2016 2020 EXECUTIVE SUMMARY OUR MISSION Our mission is to promote excellence in immunological research,
More information